Necrotising enterocolitis: To PCT or not to PCT?

A national survey of all 24 national neonatal surgical centres explored preventive strategies for necrotising enterocolitis (NEC). Particular focus was given to the use of procalcitonin (PCT) in other centres, given that Leeds neonatal units have been at the forefront of incorporating the biomarker into sepsis detection and antimicrobial stewardship. National adoption remains limited. Evidence suggests that early elevation of PCT levels may differentiatie surgical from medical NEC and improve diagnostic accuracy when combined with other markers, supporting its potential as an early biomarker of NEC severity.

Erin Frankel
Medical student

Sydnie Harris-Campbell
Medical student

School of Medicine, University of Leeds

Dr Nicola Mullins
Neonatal Consultant

Dr Liz McKechnie
Neonatal Consultant

Dr Ourania Pappa
Post CCT Neonatal SPIN Trainee (2) ourania.pappa@nhs.net

Leeds Centre for Newborn Care, Leeds Children’s Hospital

Frankel E., Harris-Campbell S., Mullins N., McKechnie L., Pappa O. Necrotising enterocolitis: To PCT or not to PCT? Infant 2025; 21(6): 174-78.

Full text available by subscription ...

The full text of this article is available to subscribers in text, and in Tablet/iPad format and as a PDF file.

Please subscribe and log in to see the full article.

Keywords

procalcitonin (PCT); necrotising enterocolitis (NEC); biomarkers

Key points

The underlying mechanisms that lead to NEC are not completely understood.
NEC is a gastrointestinal disease with a 5-12% incidence in the UK.
Determining accurate predictors of early NEC pathology has been notoriously problematic.

Also published in Infant:

VOLUME 22 ISSUE 1/FEBRUARY 2026

COLLABORATE trial to reduce mortality, NEC and cognitive impairment in babies born below 29 weeks’ gestation

We discuss COLLABORATE, a major UK-wide two-randomisation, adaptive, controlled trial to improve the care of preterm babies born below 29 weeks’ gestation. COLLABORATE aims to resolve two very longstanding uncertainties: whether preterm formula or pasteurised human donor milk is the better option to make up any shortfall in the availability of own mother’s milk, and whether human milk (own mother’s milk and pasteurised human donor milk) requires routine fortification with protein and carbohydrate. We explain the study rationale, design and importance for patients, their families and the NHS.